<DOC>
	<DOCNO>NCT01681472</DOCNO>
	<brief_summary>The purpose study compare concentration [ 6R ] 5,10-methylene-THF , 5-formyl-THF , 5-methyl-THF THF tumor , adjacent mucosa plasma patient colon cancer receive two different Modufolin® Levoleucovorin ( Isovorin® ) respectively ( 60 200 mg/m2 ) .</brief_summary>
	<brief_title>PK/PD Investigation Modufolin® Plasma , Tumor Adjacent Mucosa Patients With Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>Patients must operable colon cancer amenable curative surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Colon cancer</keyword>
	<keyword>5,10-methylenetetrahydrofolate</keyword>
	<keyword>Rectal Neoplasms</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>